Background: Post stroke cognitive impairment (PSCI) is highly prevalent across multiple cognitive domains. Individualised PSCI prognosis has mainly been researched using global cognitive outcomes. Here, we develop and externally validate clinical prediction models for overall and domain-specific PSCI, including language, memory, attention, executive function, numeracy, and praxis. Methods: N=430 stroke survivors completed the Oxford Cognitive Screen (OCS) in acute care and at 6-month follow-up (binarized outcome; impaired vs unimpaired). Logistic regression models were fitted comprising both mandatory clinically-relevant (age, sex, stroke severity, education, stroke hemisphere, acute PSCI) and data-driven (acute mood difficulties, length of stay in acute care, multimorbidity) predictors using backward elimination (p < 0.10) on multiply imputed data. Internal validation used bootstrapping to obtain optimism-adjusted performance estimates. External validation used the optimism-adjusted C-Slope as a uniform shrinkage factor. Results: Compared to the overall PSCI model (C-Statistic=0.76 [95% CI=0.71 to 0.80]), comparable or improved optimism-adjusted performance was observed in models of language (C-Statistic=0.77 [95% CI=0.72 to 0.81]) memory (C-Statistic=0.72 [95% CI=0.65 to 0.75]), and attention (C-Statistic=0.74 [0.69 to 0.78]). Numeracy (C-Statistic=0.69 [95% CI=0.63 to 0.74]), executive function (C-Statistic=0.71 [95% CI=0.65 to 0.76]), and praxis (C-Statistic=0.60 [95% CI=0.53 to 0.65]) models showed weaker performance. In external validation, the overall PSCI model was comparable to development data (C-Statistic=0.74 [95% CI=0.67 to 0.79]). Conclusions: Domain-specific prediction models have the potential to offer more meaningful PSCI prognoses compared to overall PSCI models. External performance of overall PSCI models show promise in different stroke severity cohorts. Future recalibration of memory, numeracy, executive function, and praxis models would be beneficial.

ND is a developer of the OCS but does not receive renumeration for its use.

ND (Advanced Fellowship NIHR302224) and AK (DSE Award NIHR305153) are funded by NIHR.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study uses data that is openly available at DementiaPlatforms UK https://dementiasplatforms.uk/

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes